Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0476 crossover trial in Japanese children with seasonal allergic rhinitis
2014-004774-42Phase 3
- Sponsor
- Merck & Co.
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of montelukast in seasonal allergic rhinitis (SAR) (2 arms), sponsored by Merck & Co. Primary endpoint: Change from baseline in total nasal symptom score averaged during 3 hours of exposure.
02
Drugs
montelukast
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on 2014-004774-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004774-42.